aTyr Pharma (NASDAQ:LIFE) Releases Earnings Results

aTyr Pharma (NASDAQ:LIFE) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01, Yahoo Finance reports. The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.11 million.

aTyr Pharma Price Performance

Shares of LIFE traded up $0.01 during mid-day trading on Friday, hitting $1.61. 258,118 shares of the stock were exchanged, compared to its average volume of 498,541. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.27 and a current ratio of 6.27. The company has a market cap of $109.38 million, a PE ratio of -1.68 and a beta of 1.27. aTyr Pharma has a 52-week low of $1.08 and a 52-week high of $2.70. The firm has a 50-day moving average of $1.77 and a two-hundred day moving average of $1.55.

Wall Street Analyst Weigh In

LIFE has been the topic of several recent analyst reports. Royal Bank of Canada decreased their target price on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, March 15th. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a research report on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to MarketBeat, aTyr Pharma presently has a consensus rating of “Hold” and a consensus price target of $23.67.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.